Financial reports
10-Q
2024 Q1
Quarterly report
9 May 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
14 Jun 24
8-K
Regulation FD Disclosure
6 Jun 24
8-K
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
3 Jun 24
8-K
Zura Bio Announces Participation in June Investor Conferences
29 May 24
8-K
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
9 May 24
8-K
Entry into a Material Definitive Agreement
22 Apr 24
8-K
Zura Bio Announces Robert Lisicki as CEO and Director
8 Apr 24
8-K
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
28 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Zura Bio Announces Participation at March Conferences
4 Mar 24
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
18 Jun 24
424B3
Prospectus supplement
4 Jun 24
424B7
Prospectus with selling stockholder info
31 May 24
S-1
IPO registration
24 May 24
D
$112.52 mm in equity / options / securities to be acquired, sold $112.50 mm, 19 investors
6 May 24
424B7
Prospectus with selling stockholder info
16 Oct 23
424B3
Prospectus supplement
14 Sep 23
S-1/A
IPO registration (amended)
8 Sep 23
S-1/A
IPO registration (amended)
24 Aug 23
S-1/A
IPO registration (amended)
11 Aug 23
Other
EFFECT
Notice of effectiveness
20 Jun 24
EFFECT
Notice of effectiveness
4 Jun 24
EFFECT
Notice of effectiveness
15 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
8 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
CORRESP
Correspondence with SEC
24 Aug 23
UPLOAD
Letter from SEC
17 Aug 23
CORRESP
Correspondence with SEC
11 Aug 23
UPLOAD
Letter from SEC
28 Jul 23
Ownership
4
Michael Howell
21 Jun 24
4
Gary Whale
21 Jun 24
4
Kim Davis
21 Jun 24
4
Verender S. Badial
21 Jun 24
4
Robert Lisicki
21 Jun 24
4
Kiran Nistala
21 Jun 24
4
van Amstel Arnout Ploos
23 May 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
2 May 24
SC 13G
Venrock Healthcare Capital Partners III, L.P.
2 May 24
4
Michael Howell
24 Apr 24